Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice

Diabetes

Volumn 62, Issue 6, 2013, Pages 1855-1864

  Lee, Kwang Min ^a   Yang, Seung Joo ^a   Kim, Yong Deuk ^b   Choi, Yoo Duk ^c   Nam, Jong Hee ^c   Choi, Cheol Soo ^d,e   Choi, Hueng Sik ^b   Park, Chul Seung ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Chonnam National University   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Lee Gil Ya Cancer and Diabetes Institute   (South Korea)

^e Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBLON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE DISRUPTION; GENE FUNCTION; GENOTYPE; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER; MALE; METABOLISM; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIET, HIGH-FAT; FEMALE; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, KNOCKOUT; OBESITY; PEPTIDE HYDROLASES;

EID: 84878257427     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1030     Document Type: Article

References (32)

1. Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004;63:1927-1931 (Pubitemid 39532392)
2. Jo S, Lee KH, Song S, Jung YK, Park CS. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 2005;94:1212-1224 (Pubitemid 41232577)
3. Ito T, Ando H, Suzuki T, et al. Identi fication of a primary target of thalidomide teratogenicity. Science 2010;327:1345-1350
4. Lee KM, Jo S, Kim H, Lee J, Park CS. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 2011;1813:448-455
5. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8:774-785 (Pubitemid 47462132)
6. Hawley SA, Davison M, Woods A, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 1996;271:27879-27887 (Pubitemid 26367365)
7. Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009;196:81-98
8. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-575
9. Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006;574:41-53 (Pubitemid 43905795)
10. Bergeron R, Previs SF, Cline GW, et al. Effect of 5-aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001;50:1076-1082 (Pubitemid 32374538)
11. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007;47:185-210
12. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006;3:403-416 (Pubitemid 43811782)
13. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007;104:7217-7222 (Pubitemid 47186035)
14. Ramamurthy S, Ronnett GV. Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol 2006;574:85-93 (Pubitemid 43905799)
15. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-E916 (Pubitemid 37176440)
16. Kim EJ, Yoon YS, Hong S, et al. Retinoic acid receptor-related orphan receptor a-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis. Hepatology 2012;55:1379-1388
17. Serino M, Menghini R, Fiorentino L, et al. Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007;56:2541-2546 (Pubitemid 47523261)
18. Shimano H. Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc Med 2000;10:275-278 (Pubitemid 32422104)
19. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131 (Pubitemid 34496588)
20. Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci 2002;967:7-18 (Pubitemid 34721888)
21. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-999
22. Cases S, Smith SJ, Zheng YW, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998;95:13018-13023 (Pubitemid 28509516)
23. Niu Y, Li S, Na L, et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS ONE 2012;7:e30782
24. Vaulont S, Munnich A, Decaux JF, Kahn A. Transcriptional and post-transcriptional regulation of L-type pyruvate kinase gene expression in rat liver. J Biol Chem 1986;261:7621-7625 (Pubitemid 17208678)
25. da Silva Xavier G, Leclerc I, Salt IP, et al. Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. Proc Natl Acad Sci USA 2000;97:4023-4028 (Pubitemid 30226080)
26. Viollet B, Athea Y, Mounier R, et al. AMPK: Lessons from transgenic and knockout animals. Front Biosci 2009;14:19-44
27. Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005;54:1331-1339 (Pubitemid 40586661)
28. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010;59:2781-2789
29. Fryer LG, Carling D. AMP-activated protein kinase and the metabolic syndrome. Biochem Soc Trans 2005;33:362-366 (Pubitemid 40604373)
30. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996;271:611-614 (Pubitemid 26034902)
31. Kraja AT, Lawson HA, Arnett DK, et al. Obesity-insulin targeted genes in the 3p26-25 region in human studies and LG/J and SM/J mice. Metabolism 2012;61:1129-1141
32. Davies SP, Carling D, Hardie DG. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur J Biochem 1989;186:123-128 (Pubitemid 20015134)